medigraphic.com
ISSN 0188-2198 (Impreso)

2005, Número 1

<< Anterior Siguiente >>

Rev Mex Cardiol 2005; 16 (1)


Problemas especiales Cardiopatía isquémica, insuficiencia renal crónica, diabetes mellitus, síndrome de resistencia a la insulina, enfermedad pulmonar obstructiva crónica, hipertensión renovascular

Exaire ME, Alcocer DDL, González CA, Alexanderson REG, Parra CJZ, Rodríguez SJ

Idioma: Español
Referencias bibliográficas: 33
Paginas: 43-47
Archivo PDF: 399.09 Kb.


FRAGMENTO

HIPERTENSIÓN ARTERIAL Y CARDIOPATÍA ISQUÉMICA

La enfermedad isquémica coronaria, aumenta con el grado de hipertensión.
La hipertensión arterial sistémica asociada a cardiopatía isquémica produce aumento de la frecuencia de arritmias no letales hasta en un 86% y letales en el 13%, con mayor riesgo de muerte súbita, lo que puede estar relacionado con una reducción de la reserva coronaria e hipertrofia ventricular izquierda.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Royle DT. The Framingham Study. The epidemiology of atherosclerotic disease. Massachusetts, USA, A Commonwealth Fund Book. 1980; 91-120.

  2. MacMahon S, Peto R, Cufler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.

  3. Vogt M, Motz W, Scheler S, Strauer BE. Disorders of coronary microcirculation and arrhythmias in systemic arterial hypertension. Am J Cardiol 1990; 65: 45G-50G.

  4. Zehender M, Meinertz T, Hohnloser S, Geibel A, Gerish U, Olschewski M, Just H. Prevalence of circadian variations and spontaneous variability of cardiac disorders and ECG changes suggestive of myocardial ischemia in systemic arterial hypertension. Circulation 1992; 85: 1808-1815.

  5. Francisco LL, Ferris TF. The use and abuse of diuretics. Arch Intern Med 1982; 142: 28-33.

  6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.

  7. Frishman WH, Furberg CD, Friedewald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984; 310: 830.

  8. The National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.

  9. Currie WJC, Cooper WD. Safety of angiotensin-converting enzyme inhibitors. Lancet 1985; 1: 580.

  10. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.

  11. European Society of Hypertension. European Society of Cardiology. 2003 Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.

  12. Theroux P, Taeymans Y, Waters D. Calcium antagonists: Use in the treatment of angina. Drugs 1983; 25: 179.

  13. Brown MA, Whitworth JA. Hypertension in human disease. J Hypertens 1992; 10: 701-712.

  14. Anderson S, Rennke HG, Brenner BM. Antihypertensive therapy must control glomerular hypertension to limit glomerular injury. J Hypertens 1986; 4(Suppl 5): S242-S244.

  15. Anderson S, Brenner BM. The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens 1986; 4(Suppl 5): S236-S238.

  16. Rodicio JL, Alcázar JM, Ruilope LM. Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria. Kidney Int 1990; 28: 590-594.

  17. Mann JF, Reisch C, Ritz E. Use of angiotensin converting enzyme inhibitors for the preservation of kidney function: a retrospective study. Nephron 1990; 55: S38-S42.

  18. Eliahou HE, Cohen D, Hellberg B. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988; 8: 285-290.

  19. Doyle AE, Alford F, Cooper ME, De Luise MM, Hammond J, Jerums G et al. A comparison of the effects of blood pressure reduction with perindopril and nifedipine on microalbuminuria in hypertensive and normotensive diabetics. J Hypertens 1989; 7(Suppl 6): S361.

  20. National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group Report on Hypertension and Chronic Renal Failure. Arch Intern Med 1991; 151: 1280-1287.

  21. Assman G, Schulte H. The Prospective Cardiovascular Munster (Prolam) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1998; 116: 1713-1724.

  22. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type II diabetic patients. J Hypertens 1993; 11: 319-325.

  23. Tuck M. Management of hypertension in the patients with diabetes mellitus. Focus on the use of angiotensin-converting enzyme inhibitors. Am J Hypertens 1988; 1(Suppl 2): 384S-388S.

  24. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. BMJ 1998; 317: 713-720.

  25. Edelson GW, Sowers JR. Treatment of hypertension in selected patients groups: an emphasis on diabetes mellitus and hypertension. Endocrinol 1994; 4: 205-211.

  26. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.

  27. Brown MJ. Implications from hypertension outcome trials for the management of patients with hypertension and diabetes. Br J Diabetes Vasc Dis 2003; 3: 245-251.

  28. Modan M, Halkin H, Almong S, Lusky A et al. Hyperinsulinemia, a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.

  29. González CHA. Consenso Mexicano de Resistencia a la Insulina y Síndrome Metabólico. Rev Mex Cardiol 1999; 10(1): 3-19.

  30. Ferranini E, Natali A. Essential hypertension, metabolic disorders and insulin resistance. Am Heart J 1991; 4: 1274-1282.

  31. Taddei S, Virdis A, Mattei P. Vascular renin angiotensin system and sympathetic nervous system activity in human hypertension. J Cardiovasc Pharmacol 1994; 23(Suppl): s9-s14.

  32. Wong F, Blendis L, Logan A. Effects of insulin on renal function, sympathetic nervous activity and forearm blood flow in normal human subjects. Clin Invest Med 1997; 20(5): 344-353.

  33. Chiasson J, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of Type 2 diabetes mellitus. The STOP–NIDDM Randomized Trial. Lancet 2002; 359: 2072-2077.




2020     |     www.medigraphic.com